Torque Teno病毒定量用于监测生物制剂治疗类风湿关节炎中的免疫调节
BioBio研究为多中心随机开放标签试验,纳入95例MTX应答不足的RA患者,随机接受TNFi、抗IL-6、CTLA4-Ig或抗CD20治疗并加用MTX。结果显示治疗3个月后TTV中位增加4.5×10^4 copies/ml,第3个月TTV水平与第6个月SDAI应答(P=0.03)和CDAI应答(P=0.026)相关。作者认为TTV水平在TNF、CD20和共刺激阻断后升高,并与bDMARDs临床应答相关。
要点
- 治疗3个月后TTV中位增加4.5×10^4 copies/ml(IQR 0-7.5×10^5)。
- 第3个月TTV水平与第6个月SDAI应答(P=0.03)和CDAI应答(P=0.026)相关。
- 第3个月TTV截断值1.2×10^6 c/ml预测第6个月SDAI降低85%的阳性似然比为2.7。
核心结论
- 作者认为TTV水平在TNF、CD20和共刺激阻断后升高,并与RA患者对bDMARDs的临床应答相关。
研究设计与样本
- BioBio研究为多中心随机开放标签试验,纳入对MTX应答不足的RA患者。
- 患者随机接受TNFi(英夫利西单抗,INF)、抗IL-6(托珠单抗,TCZ)、CTLA4-Ig(阿巴西普,ABA)或抗CD20(利妥昔单抗,RTX)并加用MTX。
- 采用PCR定量外周血TTV,共测量95例患者(INF n=23;TCZ n=22;ABA n=27;RTX n=23)。
主要发现
- 治疗3个月后TTV中位增加4.5×10^4 copies/ml(IQR 0-7.5×10^5)。
- 第3个月TTV水平与第6个月SDAI应答相关(P=0.03),与第6个月CDAI应答相关(P=0.026)。
- 第3个月TTV截断值1.2×10^6 c/ml预测第6个月SDAI降低85%的阳性似然比为2.7。
关键数值与推荐
- 第3个月TTV截断值1.2×10^6 c/ml预测第6个月SDAI降低85%的阳性似然比为2.7。
- 第3个月TTV水平与第6个月SDAI应答相关(P=0.03)。
- 第3个月TTV水平与第6个月CDAI应答相关(P=0.026)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: RA patients who fail to respond to MTX can receive biologic dMARDs (bDMARDs). The Torque Teno Virus (TTV) is a potential novel candidate for monitoring of immunosuppression. We explore TTV in these patients and its association with clinical response to bDMARDs. METHODS: The BioBio Study is a multicentre randomized open-label trial, including RA patients with insufficient response to MTX. Patients were randomized to either TNFi (infliximab, INF), anti-IL-6 (tocilizumab, TCZ), CTLA4-Ig (abatacept, ABA) or anti-CD20 (rituximab, RTX) in addition to MTX. PCR was used to quantify TTV in the peripheral blood. RESULTS: TTV was measured in 95 patients (INF, n = 23; TCZ, n = 22; ABA, n = 27; RTX; n = 23). TTV increased by a median of 4.5 × 104 copies/ml [c/ml; interquartile range (IQR) 0-7.5 × 105] after 3 months. TTV levels at month 3 were associated with the Simplified Disease Activity Index (SDAI) (P = 0.03) and the Clinical Disease Activity Index (CDAI) response (P = 0.026) at month 6. A TTV cut-off level of 1.2 × 106 c/ml at month 3 had a positive likelihood ratio of 2.7 for prediction of an 85% reduction in SDAI at month 6. CONCLUSION: Our data suggest that TTV levels increase upon TNF, CD20 and costimulation blockade and are associated with the clinical response to bDMARDs in RA patients. TRIAL REGISTRATION: ClinicalTrials.gov; https://clinicaltrials.gov; NCT01638715.
引用
- Studenic P, Bond G, Kerschbaumer A, et al. Torque Teno Virus quantification for monitoring of immunomodulation with biologic compounds in the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2022. PMID: 34792562. doi:10.1093/rheumatology/keab839
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。